[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

December 27, 2016

Study Completion Date

December 27, 2016

Conditions

Alzheimer's DiseaseAmnestic Mild Cognitive Impairment

Interventions

DRUG

[18F]MK-6240, ~185 MBq

IV dose of \~185 MBq \[18F\]MK-6240

DRUG

[18F]MK-6240, ~160 MBq

IV dose of \~160 MBq \[18F\]MK-6240

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02562989 - [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001) | Biotech Hunter | Biotech Hunter